Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
October 17, 2012|Oncology Practice
Author and Disclosure Information
Objectives: Investigators are comparing progression-free survival with four different chemoimmunotherapy combinations to decide which of the four regimens, if any, to take forward into a randomized, phase III trial.
Key entry or exclusion criteria: Patients must have symptomatic disease; lower-risk or high-risk permitted.
Locations: 281 sites.
Goal: 405 patients.
Study sponsor: Cancer and Leukemia Group B in collaboration with the National Cancer Institute, Eastern Cooperative Oncology Group, NCIC Clinical Trials Group, and Southwest Oncology Group.
Link for more information: clinicaltrials.gov/ct2/show/study/NCT00602459
NIH clinical trials identifier: NCT00602459